Coave Therapeutics is a clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS.
Coave Therapeutics has raised €53M across 2 funding rounds from 15 investors, most recently a Series A round in Jan 2025. Based in Saint-Jacques-de-la-Lande, France; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors |
|---|
| 2025-01-09 | Series A | €32M | Bpifrance,Fund plus,Invus,Kurma Partners,Novo Holdings,Omnes Capital+3 more | View deal → |
| 2021-07-21 | Series B | €21M | eureKARE,Fund plus,Go Capital,Idinvest,Kurma Partners,Omnes Capital+4 more | View deal → |
